Natera Inc (NTRA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Natera Inc (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8025
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers products such as panorama prenatal testing, pre-implantation genetic testing, miscarriage testing, genetic carrier screening and paternity testing. Its pre-implantation genetic testing includes translocation testing, aneuploidy screening, and single gene testing. Natera offers constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests. The company also undertakes clinical trial of several genetic materials. Natera is headquartered in San Carlos, California, the US.

Natera Inc (NTRA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Natera Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Natera Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Natera Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Natera Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Natera Inc, Medical Devices Deals, 2012 to YTD 2018 9
Natera Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Natera Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Natera Raises USD55.5 Million in Venture Financing 11
Natera Raises US$54.6 Million In Venture Financing 13
Partnerships 15
Natera Enters into Research Agreement with Neon Therapeutics 15
Natera Enters into Agreement with Imperial College London and University of Leicester 16
Natera Enters into Research Agreement with University of California, San Francisco 17
Equity Offering 18
Natera Prices Public Offering of Shares for USD90 Million 18
Natera Raises USD180 Million in IPO 20
Natera Inc – Key Competitors 22
Natera Inc – Key Employees 23
Natera Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Strategy And Business Planning 25
Jan 04, 2017: Leading Genetic Testing Companies Join Forces to Launch the Coalition for Access to Prenatal Screening 25
Financial Announcements 26
Aug 08, 2018: Natera reports second quarter 2018 financial results 26
May 08, 2018: Natera Reports First Quarter 2018 Financial Results 28
Mar 13, 2018: Natera Announces Fourth Quarter And Fiscal Year 2017 Financial Results 30
Nov 08, 2017: Natera Reports Third Quarter 2017 Financial Results 32
Aug 08, 2017: Natera Reports Second Quarter 2017 Financial Results 34
May 09, 2017: Natera Reports First Quarter 2017 Financial Results 36
Mar 07, 2017: Natera Reports Fourth Quarter and Fiscal Year 2016 Financial Results 38
Corporate Communications 40
Jul 31, 2018: Natera appoints Roy Baynes to Board of Directors adding deep oncology experience 40
Apr 09, 2018: Natera Appoints Paul R. Billings, M.D., Ph.D., as Chief Medical Officer 41
May 04, 2017: Natera Announces the Appointment of Gail Marcus as Member of the Board of Directors 42
Feb 03, 2017: Natera Announces Appointment of Mike Brophy as New Chief Financial Officer 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Natera Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Natera Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Natera Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Natera Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Natera Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Natera Inc, Medical Devices Deals, 2012 to YTD 2018 9
Natera Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Natera Raises USD55.5 Million in Venture Financing 11
Natera Raises US$54.6 Million In Venture Financing 13
Natera Enters into Research Agreement with Neon Therapeutics 15
Natera Enters into Agreement with Imperial College London and University of Leicester 16
Natera Enters into Research Agreement with University of California, San Francisco 17
Natera Prices Public Offering of Shares for USD90 Million 18
Natera Raises USD180 Million in IPO 20
Natera Inc, Key Competitors 22
Natera Inc, Key Employees 23
Natera Inc, Subsidiaries 24

List of Figures
Natera Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Natera Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Natera Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Natera Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Natera Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Natera Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Natera Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Natera Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Natera Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Natera Inc (NTRA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hoegh LNG Holdings Ltd (HLNG):企業の財務・戦略的SWOT分析
    Summary Hoegh LNG Holdings Ltd (Hoegh LNG), formerly known as Leif Hoegh & Co Ltd is an oil and gas company that offers floating energy solutions. The company's services include floating storage and regasification unit solutions, in-house ship management, floating LNG energy services, LNG regasifica …
  • ASKA Pharmaceutical Co Ltd (4514):製薬・医療:M&Aディール及び事業提携情報
    Summary ASKA Pharmaceutical Co Ltd (ASKA) is a pharmaceutical company that offers quasi-drugs, foods, medical devices and veterinary medicines. The company imports and export pharmaceuticals and medical devices. Its activities comprise production, drug information, and research and development servi …
  • Ardian Holding SAS:企業の戦略的SWOT分析
    Ardian Holding SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Noble Corporation Plc (NE):石油・ガス:M&Aディール及び事業提携情報
    Summary Noble Corporation Plc (Noble) is an offshore drilling contractor for the oil and gas industry. It provides contract drilling services with its fleet of mobile offshore drilling units. The company’s offshore rig fleet operates in the global market and provides contract drilling services. Nobl …
  • Mitsui O.S.K. Lines Ltd (9104)-石油・ガス分野:企業M&A・提携分析
    Summary Mitsui O.S.K. Lines Ltd (MOL) is a global marine logistic company. It owns and operates dry bulkers, tankers, LNG carriers, containerships, ferries & coastal RoRo ships, cruise ships. The company’s dry bulkers transport dry bulk cargo such as iron ore, coal, grains, wood, wood chips, cement, …
  • Bioasis Technologies Inc (BTI):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Suedzucker Ag
    Suedzucker Ag - Strategy, SWOT and Corporate Finance Report Summary Suedzucker Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • DSV AS (DSV):企業の財務・戦略的SWOT分析
    DSV AS (DSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Cti Engineering Co Ltd:企業の戦略・SWOT・財務分析
    Cti Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Cti Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Transelectrica SA (TEL):企業の財務・戦略的SWOT分析
    Transelectrica SA (TEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Oki Electric Industry Co., Ltd.:企業の戦略・SWOT・財務情報
    Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Oki Electric Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Avangrid Renewables LLC:電力:M&Aディール及び事業提携情報
    Summary Avangrid Renewables LLC (Avangrid Renewables) a subsidiary of Avangrid Renewables Holdings, Inc., is a renewable energy company that carries out electricity generation from renewable energy sources including wind, biomass, solar energy and thermal energy. The company also provides services s …
  • Sopharma AD (3JR):製薬・医療:M&Aディール及び事業提携情報
    Summary Sopharma AD (Sopharma) develops, manufactures and commercializes medicinal substances and finished dosage forms. The company focuses on the production of pharmaceutical products; substances and preparations; veterinary vaccines; infusion solutions; hemodialysis concentrates; medical disposab …
  • Sutter Health:企業の戦略的SWOT分析
    Sutter Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • UMN Pharma Inc (4585):企業の財務・戦略的SWOT分析
    Summary UMN Pharma Inc (UMN Pharma), a subsidiary of Shionogi Inc, is a biopharmaceutical company that manufactures therapeutic for muscular dystrophy, diabetes and influenza. The company’s pipeline products include UMN-101 for the treatment of Recombinant seasonal influenza vaccine; UMN-102 for rec …
  • Nuclear Decommissioning Authority:企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Repsol SA (REP):石油・ガス:M&Aディール及び事業提携情報
    Summary Repsol SA (Repsol) is an integrated oil and gas company. It has presence across the entire value chain: exploration and production, transformation, development and marketing of energy. The company’s upstream business carries out oil and natural gas exploration and production. Its downstream …
  • Paion AG (PA8):企業の財務・戦略的SWOT分析
    Summary Paion AG (Paion) is a specialty pharmaceutical company that focuses on the development and commercialization of drugs used for out-patient and hospital-based sedation, anesthesia and critical care services. The company’s lead product, remimazolam, is designed for the treatment of patients re …
  • HCR ManorCare Inc:企業の戦略・SWOT・財務情報
    HCR ManorCare Inc - Strategy, SWOT and Corporate Finance Report Summary HCR ManorCare Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Trianni Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Trianni Inc (Trianni) is a developer of fully human monoclonal antibodies that provides its propriety discovery platform. The company provides Trianni Mouse platform that holds engineered versions of three antibody-encoding genetic loci, namely, Heavy, Kappa, Lambda, and others. It enables t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆